VIA EDGAR
May 25, 2021
Office of Life Sciences
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Irene Paik, Joe McCann, Tara Harkins and Dan Gordon
| Re: | Centessa Pharmaceuticals plc | |||
| Acceleration Request for Registration Statement on Form S-1 | ||||
| File No. 333-255393 | ||||
| Requested Date: | May 27, 2021 | |||
| Requested Time: | 4:00 p.m. Eastern Time | |||
Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Centessa Pharmaceuticals plc (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 27, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling James Xu at (617) 570-1483. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: James Xu, by facsimile to (617) 801-8979.
[Remainder of page left intentionally blank]
If you have any questions regarding this request, please contact James Xu of Goodwin Procter LLP at (617) 570-1483.
| Sincerely, |
| CENTESSA PHARMACEUTICALS PLC |
/s/ Saurabh Saha, M.D., Ph.D. |
| Name: Saurabh Saha, M.D., Ph.D. |
| Title: Chief Executive Officer |
| cc: | Gregory Weinhoff, M.D., M.B.A., Centessa Pharmaceuticals plc |
Marella Thorell, Centessa Pharmaceuticals plc
Iqbal Hussain, Centessa Pharmaceuticals plc
Mitchell Bloom, Goodwin Procter LLP
Edwin O’Connor, Goodwin Procter LLP
James Xu, Goodwin Procter LLP
[Signature Page to Acceleration Request]
